Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives
Julie E. Bauman(George Washington University), Athanassios Argiris(The University of Texas at San Antonio Health Science Center), William E. Gooding(UPMC Hillman Cancer Center), Dwight E. Heron(Bon Secours Mercy Health), Umamaheswar Duvvuri(City University of New York), A. Wehbe(The University of Texas at San Antonio Health Science Center), Malabika Sen(University of Pittsburgh Medical Center), Sufi M. Thomas(University of New Mexico), Jennifer R. Grandis(University of California, San Francisco), Seungwon Kim(UPMC Hillman Cancer Center), Frank R. Miller(The University of Texas at San Antonio Health Science Center), David A. Clump(West Virginia University), Brian J Karlovits(Bon Secours Mercy Health)
Cited by 14
Related Papers
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590